BioNexus Gene Lab Corp financial data

Symbol
BGLC on Nasdaq
Industry
Services-Medical Laboratories
Location
10 2 Tower B, Vertical Business Suite,, 8 Jalan Kerinchi,, Kuala Lumpur, Malaysia
State of incorporation
WY
Fiscal year end
December 31
Former names
BioNexus Gene Lab Coporation (to 5/8/2020)
Latest financial report
10-Q - Q3 2024 - Nov 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 500 % +42%
Quick Ratio 75.3 % +28.5%
Debt-to-equity 17.8 % -33.3%
Return On Equity -9.93 % +77.7%
Return On Assets -8.43 % +75.3%
Operating Margin -9.72 % +66.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18M shares +1.7%
Common Stock, Shares, Outstanding 18M shares +0.98%
Entity Public Float 66.5M USD
Common Stock, Value, Issued 17.3M USD +0.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 9.26M USD -10.4%
Cost of Revenue 8.01M USD -10.3%
General and Administrative Expense 3.52M USD -28.4%
Operating Income (Loss) -900K USD +69.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -919K USD +69.2%
Income Tax Expense (Benefit) -172K USD -13173%
Net Income (Loss) Attributable to Parent -942K USD +69.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.84M USD -25.5%
Inventory, Net 1.39M USD +25.4%
Assets, Current 7.04M USD -14.9%
Property, Plant and Equipment, Net 1.73M USD +15.5%
Operating Lease, Right-of-Use Asset 233K USD +64.4%
Assets 11M USD -4.1%
Accounts Payable, Current 1.03M USD -34.2%
Liabilities, Current 1.41M USD -13.9%
Deferred Income Tax Liabilities, Net 13.6K USD -52.7%
Operating Lease, Liability, Noncurrent 178K USD +70.1%
Liabilities 1.61M USD -9.61%
Accumulated Other Comprehensive Income (Loss), Net of Tax -162K USD +79.8%
Retained Earnings (Accumulated Deficit) -3.09M USD -73.7%
Stockholders' Equity Attributable to Parent 9.39M USD +0.77%
Liabilities and Equity 11M USD -4.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34.4K USD +70.4%
Net Cash Provided by (Used in) Financing Activities 24.2K USD
Net Cash Provided by (Used in) Investing Activities 24.1K USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 17.7M shares +22%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -97.2K USD +33.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.14M USD -32.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.66K USD +90.6%
Operating Lease, Liability 25.3K USD
Depreciation 20.1K USD -3.63%
Payments to Acquire Property, Plant, and Equipment 102 USD -99.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 21.1K USD +88.6%
Property, Plant and Equipment, Gross 2.51M USD +4.59%
Operating Lease, Liability, Current 48.2K USD +42.2%
Deferred Income Tax Expense (Benefit) 16K USD +886%
Preferred Stock, Shares Authorized 30M shares 0%
Additional Paid in Capital -5.01M USD 0%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 34.6K USD +103%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 0 USD -100%
Operating Leases, Future Minimum Payments, Due in Three Years 30.3K USD +170%
Operating Leases, Future Minimum Payments Due 133K USD +135%
Interest Expense 6.19K USD +45.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares